It is a pharma private limited company based in New Delhi, Delhi, India, established in 2008.
2008 | New Delhi, Delhi, India | Struck OffAccure Oncology Labs Private Limited, a struck off private limited company, was established on 15 April 2008 in New Delhi, Delhi, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24232DL2008PTC176795. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Its leadership includes Ajay Vikram Singh (Director), Asit Chandra Bose (Director). Past directors included Brij Sarin, Sandeep Sharadaprasad Srivastava, Ajay Vikram Singh. Its latest AGM occurred on 30 September 2019, with the balance sheet filed on 31 March 2019. It is based at Flat No.1406A, 14Th Floor Building No. 89, Hemkunth Chamber, Nehru, Place, New Delhi, Delhi, 110019.
U24232DL2008PTC176795
176795
15 April 2008
₹1.00 M
₹0.10 M
Roc Delhi
Unlisted
Struck Off
Explore comprehensive insights into Accure Oncology Labs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ajay Vikram Singh | Director | 23 Mar 2017 | Current |
| Asit Chandra Bose | Director | 27 Jul 2016 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 30 Mar 2017 | Past |
| Pramod Abcsdd | Director | 06 Oct 2014 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2017 | Past |
| Pramod Abcsdd | Director | 06 Feb 2017 | Past |
| Pramod Abcsdd | Director | 11 Aug 2015 | Past |
| Pramod Abcsdd | Additional Director | 29 Jul 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Accure Oncology Labs Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 81.66% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.84%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2017, Accure Oncology Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Accure Oncology Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Accure Oncology Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Accure Oncology Labs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Accure Oncology Labs Private Limited last Annual general meeting of members was held on 30 Sep 2019 as per latest MCA records. was documented.
Accure Oncology Labs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2019 with Roc Delhi. was recorded as a recent event.
Progress on Ajay Vikram Singh was appointed as a Director was appointed as a Director on 23 Mar 2017 & has been associated with this company since 8 years 8 months . was documented.
Progress on Asit Chandra Bose was appointed as a Director was appointed as a Director on 27 Jul 2016 & has been associated with this company since 9 years 4 months . was documented.
The activity Accure Oncology Labs Private Limited was registered on 15 Apr 2008 with Roc Delhi & aged 17 years 8 months as per MCA records. was completed.
The CIN of Accure Oncology Labs Private Limited is U24232DL2008PTC176795.
Accure Oncology Labs Private Limited is headquartered at Flat No.1406A, 14Th Floor Building No. 89, Hemkunth Chamber, Nehru, Place, New Delhi, Delhi, 110019.
Accure Oncology Labs Private Limited was incorporated on 15 April 2008.
The current directors of Accure Oncology Labs Private Limited are
The primary industry of Accure Oncology Labs Private Limited is Trade.
Accure Oncology Labs Private Limited is unlisted.
The authorized capital of Accure Oncology Labs Private Limited is ₹1.00 M, and the paid-up capital is ₹0.10 M.
The compliance status of Accure Oncology Labs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX